Oflo 700 Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, designed for the treatment of a broad spectrum of bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal action by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication, transcription, and repair, thereby effectively targeting aerobic Gram-positive and Gram-negative bacteria. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing strand breakage. This synergistic combination makes Oflo 700 Tablet particularly useful in managing mixed infections involving both aerobic and anaerobic organisms, such as gastrointestinal infections, genitourinary tract infections, respiratory tract infections, skin and soft tissue infections, and certain sexually transmitted infections. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection, patient age, and renal function. Caution is advised in patients with hypersensitivity to fluoroquinolones or nitroimidazoles, and potential side effects may include gastrointestinal disturbances, dizziness, and hypersensitivity reactions. Oflo 700 Tablet is contraindicated during pregnancy and lactation unless deemed essential by a physician. Proper adherence to the prescribed regimen is crucial to prevent resistance development.